Spotlight On... J&J, AbbVie swell Imbruvica patient pool with first-line FDA nod in CLL; Advair safety profile comparable to Flonase's, GSK says; Jimmy Carter doesn't need melanoma treatment after Merck's Keytruda; and more...

AbbVie ($ABBV) has said it expects nearly a third of Imbruvica's future growth to come from moving into earlier lines of therapy in the drug's approved indications. And Friday, the therapy did just that, snagging a first-line go-ahead from the FDA in patients with chronic lymphocytic leukemia (CLL). More from FiercePharma

> Amid a shortage of doctors and a tide of new patients with insurance under the Affordable Care Act, an increasing number of states are granting physician assistants more autonomy. Report

> Study data published in the New England Journal of Medicine shows Advair's safety profile is comparable to that of Flonase, GlaxoSmithKline ($GSK) says. Release

> Royalty Pharma has purchased UCLA's royalty rights connected with prostate cancer pill Xtandi. Release

> The FDA has approved CSL Behring's Idelvion, a hemophilia B therapy with dosing intervals of up to two weeks. Release

 > GSK says it has confirmed the safety profile of respiratory med Nucala with a long-term study that showed similar results to previous trials. Release

And Finally... U.S. President Jimmy Carter says he'll no longer need treatment for melanoma after receiving Merck ($MRK) immunotherapy Keytruda. Report

Suggested Articles

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.